(Q46233638)

English

Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group

scientific article published in January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

Anna Dmoszyńska

6

object named as

Anna Dmoszynska

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

7

object named as

Lech Konopka

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

Krzysztof Warzocha

8

object named as

Krzysztof Warzocha

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

1

object named as

Tadeusz Robak

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

Joanna Góra-Tybor

4

object named as

Joanna Gora-Tybor

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

Krzysztof Jamroziak

9

object named as

Krzysztof Jamroziak

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

Jerzy Z. Blonski

2

object named as

Jerzy Z Blonski

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

author name string

Ewa Wawrzyniak

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

Aleksandra Palacz

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

language of work or name

0 references

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

115

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

94-100

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

New prognostic markers in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

p53 in health and disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

21 January 2018

Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

7 January 2021

based on heuristic

inferred from DOI database lookup

Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24003

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24003

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19025975

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46233638&oldid=2101711078"